Glycemic Targets in Type 2 Diabetes
For many nonpregnant adults with type 2 diabetes, an A1C target of <7% is recommended (often Class 2A/2B level guidance depending on the specific subrecommendation presented in the Standards of Care glycemic goals section). [1]
For blood glucose targets, a preprandial (fasting) plasma glucose 80–130 mg/dL (4.4–7.2 mmol/L) and a postprandial (peak) glucose <180 mg/dL (10.0 mmol/L) are suggested as targets for many adults. [2]
Stepwise Management Plan for Type 2 Diabetes (Glucose Lowering)
Treatment should include healthy behaviors and diabetes self-management education and support, with ongoing avoidance of therapeutic inertia. [3]
Glucose-lowering medication selection should be guided by the need to achieve individualized glycemic goals, minimize hypoglycemia risk, reduce treatment burden, and address comorbidity and medication access considerations via shared decision-making. [3]
Initial Pharmacologic Therapy
Metformin is the preferred initial pharmacologic agent when appropriate based on clinical factors. [3]
Metformin is commonly used as first-line therapy because it is effective for A1C lowering, is weight neutral, does not cause hypoglycemia when used as monotherapy, and is inexpensive and widely available. [3]
Intensification After Inadequate Glycemic Response
When A1C is ≥1.5% above the individualized glycemic goal, intensification of glucose-lowering therapy is recommended rather than maintaining monotherapy. [3]
For intensification, combination therapy is typically used, with selection based on glycemic efficacy, side effect profile, and access and affordability. [3]
Indications for Early Injectable Therapy
Insulin should be considered as first injectable therapy when there are symptoms of hyperglycemia or when A1C or blood glucose values are very high, including A1C >10% or blood glucose ≥300 mg/dL. [3]
Medication Class Selection Framework (Examples)
The following medication classes are used for glucose lowering based on individualized priorities such as glycemic efficacy and comorbidity/organ-protection goals, with specific agents selected through shared decision-making:
- Thiazolidinediones (including pioglitazone). [3]
- GLP-1 receptor agonists (including semaglutide, dulaglutide). [3]
- GIP and GLP-1 receptor agonist (including tirzepatide, where indicated/available). [3]
- SGLT2 inhibitors (including empagliflozin, dapagliflozin, canagliflozin). [3]
- DPP-4 inhibitors (including sitagliptin, linagliptin). [3]
- Sulfonylureas (including glimepiride). [3]
- Meglitinides (including repaglinide). [3]
- Basal insulin (including insulin glargine or NPH insulin), with advancement to injectable combination therapy when needed to achieve goals. [3]
Treatment Targets and Monitoring Time Course
A1C is used to assess glycemic status and guide titration of therapy. [1]
Preprandial glucose targets are 80–130 mg/dL for many adults, and peak postprandial targets are <180 mg/dL for many adults. [2]
Common Pitfalls to Avoid
Therapeutic inertia should be avoided by reassessing treatment efficacy and safety and intensifying therapy when glycemic goals are not met. [3]
Medication plans should be continuously reviewed for efficacy, side effects, hypoglycemia risk, and treatment burden. [3]
Misalignment with individualized goals is a clinical pitfall, since A1C targets should be individualized based on patient characteristics and risks. [1]
Glycemic Goal Deintensification for Safety
Lowering or modifying therapy is recommended when hypoglycemia risk goals are not met in patients using CGM metrics, including deintensification or therapy modification to reduce hypoglycemia exposure. [1]
Lower A1C goals (e.g., <6.5%) may be appropriate for individuals with good health and low treatment risk, while less stringent goals may be appropriate when treatment harms exceed benefits. [1]